News

A new therapeutic strategy for more aggressive lung tumor

Lung cancer is one of the most prevalent, with more than 20,000 new cases diagnosed each year in Spain. In 30% intervenes KRAS oncogene, which causes more aggressive tumor. It is also a type of lung cancer that does not has targeted therapies beyond the standard cisplatin. A study led by researchers Mariano Barbacid and […]

Leer más about A new therapeutic strategy for more aggressive lung tumor

Eva Gonzalez Suarez gets Consolidator Grant from the European Research Council

The head of the group of Transformation and Metastasis PEBC-IDIBELL, Eva Gonzalez Suarez has received an ERC Consolidator Grant from the European Research Council (ERC) to develop its PLEIO-RANK project to develop a single therapy capable of reducing metastasis and mortality in solid tumors. The grant supposes a funding 2 million Euros for the next five years.

Leer más about Eva Gonzalez Suarez gets Consolidator Grant from the European Research Council

Researcher Oriol Casanovas received a Proof of Concept 2015 grant awarded by the European Union

The European Research Council (ERC) has announced the names of the scientists who will receive the Proof of Concept (PoC) 2015 grant, which is only accessible to scientists who already have a grant from the ERC. Oriol Casanovas, leader of the Tumor Angiogenesis group of the PROCURE program from ICO and IDIBELL has been one […]

Leer más about Researcher Oriol Casanovas received a Proof of Concept 2015 grant awarded by the European Union

UB invest doctor honoris causa the oncologist and epidemiologist Francesc Xavier Bosch

The oncologist and epidemiologist Francesc Xavier Bosch has been awarded an honorary doctorate (Honoris Causa) by the University of Barcelona today February 11th, 2016. At the ceremony, which was held in the Paranimf, have acted as guarantors Francesc Cardellach, dean of the Faculty of Medicine, UB, and Victor Raul Moreno, professor of the Department of […]

Leer más about UB invest doctor honoris causa the oncologist and epidemiologist Francesc Xavier Bosch

DNA fingerprinting, a key for the survival of cancer patients who do not respond to standard treatments

Jaume Giró, General Manager of the “La Caixa” Bank Foundation, and Manel Esteller, director of the Epigenetics and Cancer Biology Program of the Bellvitge Institute of Biomedical Research (IDIBELL), have presented today a pioneering study on epigenetic prediction of drug response to optimize cancer therapy in patients who no longer respond to standard treatments. The […]

Leer más about DNA fingerprinting, a key for the survival of cancer patients who do not respond to standard treatments

ERDF funds enable the incorporation of CMRB to IDIBELL’s facilities

The Direcció General de Recerca de la Secretaria d’Universitats i Recerca (Departament d’Empresa i Coneixement) has granted a project to Bellvitge Biomedical Research Institute (IDIBELL) for the optimization, adaptation, improvement of facilities and acquisition of technological equipment at  IDIBELL because of  the forthcoming integration of the Center for Regenerative Medicine in Barcelona (CMRB) in these spaces. […]

Leer más about ERDF funds enable the incorporation of CMRB to IDIBELL’s facilities
Scroll to Top